StockData
Q32 Bio Inc. logo

Q32 Bio Inc. (QTTB) stock

QTTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$8.63+0.34 (+4.10%)

Close on Nov 17, 2026Market cap $256.91MP/E –Yield –

Q32 Bio r&d expenses

Research and development expenses are spending on new products and technology.

Q32 Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $14.35M, down 61.4% year over year. For fiscal 2025 it was $19.16M, down 60.2% from the year before. The highest annual figure on record is $100.39M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$19.16M-60.2%
FY2024Dec 31, 2024$48.14M+51.7%
FY2023Dec 31, 2023$31.73M-67.7%
FY2022Dec 31, 2022$98.35M+5.7%
FY2021Dec 31, 2021$93.09M-7.3%
FY2020Dec 31, 2020$100.39M+12.3%
FY2019Dec 31, 2019$89.40M+86.4%
FY2018Dec 31, 2018$47.95M+124.3%
FY2017Dec 31, 2017$21.38M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.26M-17.5%
Q1 FY2026Mar 31, 2026$3.22M-54.8%
Q4 FY2025Dec 31, 2025$3.32M-68.6%
Q3 FY2025Sep 30, 2025$3.56M-75.2%
Q2 FY2025Jun 30, 2025$5.16M-61.5%
Q1 FY2025Mar 31, 2025$7.12M-27.6%
Q4 FY2024Dec 31, 2024$10.55M+26.5%
Q3 FY2024Sep 30, 2024$14.35M+92.2%
Q2 FY2024Jun 30, 2024$13.41M+67.3%
Q1 FY2024Mar 31, 2024$9.84M+24.4%
Q4 FY2023Dec 31, 2023$8.34M-69.3%
Q3 FY2023Sep 30, 2023$7.46M-71.1%
Q2 FY2023Jun 30, 2023$8.02M-62.0%
Q1 FY2023Mar 31, 2023$7.91M-67.4%
Q4 FY2022Dec 31, 2022$27.15M+14.8%
Q3 FY2022Sep 30, 2022$25.85M+7.8%
Q2 FY2022Jun 30, 2022$21.08M-11.1%
Q1 FY2022Mar 31, 2022$24.27M+11.6%
Q4 FY2021Dec 31, 2021$23.65M+1.9%
Q3 FY2021Sep 30, 2021$23.99M+17.5%
Q2 FY2021Jun 30, 2021$23.70M-13.7%
Q1 FY2021Mar 31, 2021$21.76M-25.8%
Q4 FY2020Dec 31, 2020$23.20M+14.0%
Q3 FY2020Sep 30, 2020$20.42M-20.5%
Q2 FY2020Jun 30, 2020$27.47M+20.3%
Q1 FY2020Mar 31, 2020$29.31M+42.7%
Q4 FY2019Dec 31, 2019$20.34M+24.9%
Q3 FY2019Sep 30, 2019$25.69M+91.8%
Q2 FY2019Jun 30, 2019$22.83M+121.8%
Q1 FY2019Mar 31, 2019$20.54M+156.8%
Q4 FY2018Dec 31, 2018$16.28M+70.0%
Q3 FY2018Sep 30, 2018$13.39M+170.8%
Q2 FY2018Jun 30, 2018$10.29M+153.7%
Q1 FY2018Mar 31, 2018$8.00M+185.7%
Q4 FY2017Dec 31, 2017$9.58M–
Q3 FY2017Sep 30, 2017$4.95M–
Q2 FY2017Jun 30, 2017$4.06M–
Q1 FY2017Mar 31, 2017$2.80M–

More Q32 Bio figures

See a number that looks wrong?